I expected the buying to stop last friday after earnings, put the volume keeps chugging along. Still hitting 500K+ volume per day when you would expect a little over 100K. Is it because of the potential partnering of PSMA ADC next year?
cafisherman, that is what I was thinking. The increased sales estimates for Relistor in AMI puts a higher floor in for PGNX no matter what happens with the chronic pain indication. The data from the phase II study of the anti-PMSA antibodies will drive PGNX now, and we sure as hell will need a partner with expertise AND cash in oncology. By the way the volume and upward move of PGNX has been very impressive and very satisfying long overdue. It has gotten me close to the point where I beginning to think about selling some PGNX.